Diffuse Large B-cell Lymphoma (DLBCL)
Diffuse large B-cell lymphoma (DLBCL) is a prevalent and aggressive subtype of non-Hodgkin lymphoma (NHL), accounting for a significant proportion of lymphoma cases worldwide. DLBCL is characterized by the rapid growth of large B-cells in lymphoid tissues. Our company is at the forefront of DLBCL drug and therapy development services, aiming to provide personalized drug discovery and development services. By leveraging our scientific expertise and collaborative approach, we strive to deliver innovative and effective therapies that address the unmet needs of DLBCL.
Overview of DLBCL
Diffuse large B-cell lymphoma (DLBCL) is characterized by the proliferation of large B-cells, which can arise from either germinal center B-cells (GCB) or activated B-cell-like (ABC) cells. The annual incidence of new cases of diffuse large B-cell lymphoma is 5.5 cases per 100,000. DLBCL typically presents as rapidly growing tumors in lymph nodes, but it can also involve extranodal sites. The presentation may vary, with symptoms including enlarged lymph nodes, fever, night sweats, and weight loss. DLBCL is a heterogeneous disease, and its classification based on gene expression profiling has led to personalized DLBCL therapy development approaches.
Pathogenesis of DLBCL
DLBCL is a complex disease with multiple genetic and molecular alterations driving its pathogenesis. Translocations involving the MYC, BCL2, and BCL6 genes are commonly observed in DLBCL and have been associated with aggressive disease and poorer outcomes. Dysregulation of various signaling pathways, including the B-cell receptor (BCR) pathway, NF-κB pathway, and PI3K-AKT-mTOR pathway, contributes to the survival and proliferation of DLBCL cells. Additionally, alterations in epigenetic regulators, such as DNA methylation and histone modifications, play a role in DLBCL development.
Fig.1 Cytotoxic effects of Chidamide in DLBCL cells. (Wu, Chunyan, et al., 2024)Diagnostic Development of DLBCL
- Immunophenotyping using immunohistochemistry (IHC) or flow cytometry helps determine the cell of origin (GCB vs. non-GCB/ABC) and assess the expression of various markers, including CD20, CD10, BCL6, and MUM1/IRF4.
- Genetic testing, such as fluorescence in situ hybridization (FISH) or next-generation sequencing (NGS), can identify specific genetic alterations, such as MYC, BCL2, and BCL6 translocations.
Therapeutics Development of DLBCL
- Targets of DLBCL Therapy Development
Numerous targets have been identified in DLBCL, offering opportunities for targeted therapies. These targets encompass various cellular pathways and immunological components involved in DLBCL pathogenesis. Some of the key targets include:
- B-cell Receptor (BCR) Signaling
- CD19
- Immune Checkpoints
- Epigenetic Modifiers
- PI3K-AKT-mTOR Pathway
- Other Potential Targets
- Types of DLBCL Therapy Development
- Immunotherapy
-Anti-CD19 CAR T cells
-CAR-NK Cells
-Bispecific T Cell Engagers
- Therapeutic Antibodies
-CD20 Targeted Therapy
-CD79b Targeted Therapy
-CD19 Targeted Therapy
-CD22 Targeted Therapy
-CD30 Targeted Therapy
-CD74 Targeted Therapy
- Molecular Pathway Inhibition Therapies
-BCR Signaling Pathway Inhibition
-BCL-2 Inhibition
-VEGFR Inhibition
-PI3K/Akt/mTOR Inhibition
-NF-κB Pathway Inhibition
-JAK/STAT3 Inhibition
- Epigenetic-modifying Drugs
-Histone Deacetylase Inhibition
-EZH2 Inhibition
-Bromodomain Inhibition
Our Services
In the evolving field of DLBCL diagnostics and therapy development, our company serves our customers with unwavering commitment and relentless innovation. With many years of experience, we have a mature platform and team in the field of DLBCL research.
Platforms of DLBCL Therapy Development
We work with determination to develop rare disease models utilizing a host of cutting-edge technologies, and we provide diverse animal species to support studies of pharmacokinetic properties and safety of potential therapies.
Our DLBCL animal model development services include but are not limited to
- Autochthonous animal models
- Cluster 1/BN2 models
- Cluster 2/A53 models
- Cluster 3/EZB DLBCL models
- Cluster 4/ST2 models
- Cluster 5/MCD models
Our meticulously crafted suite of services stands as a testament to our unwavering commitment, leaving no stone unturned in our relentless pursuit of scientific advancement. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Wu, Chunyan, et al. "Targeting HDACs for diffuse large B-cell lymphoma therapy." Scientific Reports 14.1 (2024): 289.
- Wang, Liang, Lin-rong Li, and Ken H. Young. "New agents and regimens for diffuse large B cell lymphoma." Journal of hematology & oncology 13 (2020): 1-23.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.